Search

Your search keyword '"Shimazu, Yutaka"' showing total 203 results
Start Over Author "Shimazu, Yutaka"
203 results on '"Shimazu, Yutaka"'

1. The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients

Author

Shimazu, Yutaka, Kanda, Junya, Takakuwa, Teruhito, Onda, Yoshiyuki, Fukushima, Kentaro, Hotta, Masaaki, Fuchida, Shin-ichi, Uoshima, Nobuhiko, Shimura, Yuji, Tanaka, Hirokazu, Ohta, Kensuke, Shibayama, Hirohiko, Kosugi, Satoru, Yagi, Hideo, Yoshihara, Satoshi, Hosen, Naoki, Ito, Tomoki, Shimazaki, Chihiro, Matsumura, Itaru, Kuroda, Junya, Takaori-Kondo, Akifumi, and Hino, Masayuki

Published
2024
Full Text
View/download PDF

2. Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study

Author

Kurosawa, Shuhei, Shimomura, Yoshimitsu, Ishiyama, Ken, Fuse, Kyoko, Shimazu, Yutaka, Doki, Noriko, Uchida, Naoyuki, Tanaka, Masatsugu, Takahashi, Satoshi, Sakurai, Masatoshi, Kobayashi, Hikaru, Katayama, Yuta, Takada, Satoru, Ozeki, Kazutaka, Nakamae, Hirohisa, Ishimaru, Fumihiko, Kanda, Yoshinobu, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Itonaga, Hidehiro

Published
2024
Full Text
View/download PDF

3. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

Author

Shimazu, Yutaka, Kanda, Junya, Onda, Yoshiyuki, Fuchida, Shin-ichi, Ohta, Kensuke, Shimura, Yuji, Kosugi, Satoru, Yamamura, Ryosuke, Matsuda, Mitsuhiro, Hanamoto, Hitoshi, Adachi, Yoko, Anzai, Naoyuki, Hotta, Masaaki, Fukushima, Kentaro, Yagi, Hideo, Yoshihara, Satoshi, Tanaka, Yasuhiro, Takakuwa, Teruhito, Tanaka, Hirokazu, Shibayama, Hirohiko, Uoshima, Nobuhiko, Hosen, Naoki, Ito, Tomoki, Shimazaki, Chihiro, Matsumura, Itaru, Kuroda, Junya, Takaori-Kondo, Akifumi, and Hino, Masayuki

Published
2024
Full Text
View/download PDF

6. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Author

Shimazu, Yutaka, Kanda, Junya, Kosugi, Satoru, Ito, Tomoki, Kaneko, Hitomi, Imada, Kazunori, Shimura, Yuji, Fuchida, Shin-ichi, Fukushima, Kentaro, Tanaka, Hirokazu, Yoshihara, Satoshi, Ohta, Kensuke, Uoshima, Nobuhiko, Yagi, Hideo, Shibayama, Hirohiko, Yamamura, Ryosuke, Tanaka, Yasuhiro, Uchiyama, Hitoji, Onda, Yoshiyuki, Adachi, Yoko, Hanamoto, Hitoshi, Takahashi, Ryoichi, Matsuda, Mitsuhiro, Miyoshi, Takashi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, and Kuroda, Junya

Published
2023
Full Text
View/download PDF

7. Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma

Author

Okada, Yosuke, Kimura, Fumihiko, Kurita, Naoki, Takahashi, Hiroyuki, Shimazu, Yutaka, Mizuno, Shohei, Uchida, Naoyuki, Kataoka, Keisuke, Hiramoto, Nobuhiro, Ota, Shuichi, Kako, Shinichi, Tsukada, Nobuhiro, Kanda, Yoshinobu, Kurahashi, Shingo, Doki, Noriko, Nishikawa, Akinori, Kim, Sung-Won, Hangaishi, Akira, Kanda, Junya, Fukuda, Takahiro, Atsuta, Yoshiko, Kondo, Eisei, Kawamura, Koji, and Nakasone, Hideki

Published
2023
Full Text
View/download PDF

10. Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors.

Author

Nakajima, Takako Eguchi, primary, Kuboki, Yasutoshi, additional, Fukahori, Masaru, additional, Shimazu, Yutaka, additional, Kondo, Shunsuke, additional, Katsuya, Yuki, additional, Ikeda, Masafumi, additional, Satake, Tomoyuki, additional, Kagehara, Hideaki, additional, Akaike, Takenori, additional, Singh, Aman P, additional, Atkuri, Kondala, additional, Pop-Damkov, Petar, additional, Tamada, Koji, additional, and Koyama, Takafumi, additional

Published
2024
Full Text
View/download PDF

11. Autologous hematopoietic cell transplantation for myeloma patients with hepatitis B virus or hepatitis C virus in the era of novel agents

Author

Mizuno, Shohei, Takami, Akiyoshi, Takamatsu, Hiroyuki, Hanamura, Ichiro, Shimazu, Yutaka, Hangaishi, Akira, Tsukada, Nobuhiro, Kako, Shinichi, Kikuchi, Taku, Ota, Shuichi, Shimizu, Hiroaki, Iida, Shinsuke, Yoshioka, Satoshi, Sawa, Masashi, Fukuda, Takahiro, Kanda, Yoshinobu, Atsuta, Yoshiko, and Kawamura, Koji

Published
2022
Full Text
View/download PDF

13. Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis

Author

Suzuki, Kazuhito, Shimazu, Yutaka, Minakata, Daisuke, Ikeda, Takashi, Takahashi, Hiroyuki, Tsukada, Nobuhiro, Kanda, Yoshinobu, Doki, Noriko, Nishiwaki, Kaichi, Miwa, Akiyoshi, Sawa, Masashi, Kataoka, Keisuke, Hiramoto, Nobuhiro, Ota, Shuichi, Itagaki, Mitsuhiro, Ichinohe, Tatsuo, Atsuta, Yoshiko, Yano, Shingo, and Kawamura, Koji

Published
2023
Full Text
View/download PDF

14. The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation.

Author

Shimazu, Yutaka, Kanda, Junya, Suzuki, Kazuhito, Wada, Akinori, Kikuchi, Taku, Ikeda, Takashi, Tsukada, Nobuhiro, Miwa, Akiyoshi, Itagaki, Mitsuhiro, Kako, Shinichi, Nishiwaki, Kaichi, Ota, Shuichi, Fujiwara, Shin‐ichiro, Kataoka, Keisuke, Doki, Noriko, Sawa, Masashi, Hiramoto, Nobuhiro, Nishikawa, Akinori, Imai, Toshi, and Ichinohe, Tatsuo

Abstract

The anti‐CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent ASCT between 2017 and 2020. In the comparison between patients not administered Dara (Dara– group) and those administered Dara (Dara+ group), the 1‐year progression‐free survival (PFS) rates were 87.4% and 77.3% and the 1‐year overall survival (OS) rates were 96.7% and 90.0%, respectively. In multivariate analysis, age <65 years (p = 0.015), low international staging system (ISS) stage (p < 0.001), absence of unfavorable cytogenic abnormalities (p < 0.001), no Dara use before ASCT (p = 0.037), and good treatment response before ASCT (p < 0.001) were independently associated with superior PFS. In matched pair analysis, the PFS/OS of the Dara– group were also significantly superior. For MM patients who achieved complete or very good partial response (CR/VGPR) by Dara addition before ASCT, both PFS and OS significantly improved. However, in patients who did not achieve CR/VGPR before ASCT, the PFS/OS of the Dara+ group were significantly inferior to those of the Dara– group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study

Author

Kurosawa, Shuhei, primary, Shimomura, Yoshimitsu, additional, Ishiyama, Ken, additional, Fuse, Kyoko, additional, Shimazu, Yutaka, additional, Doki, Noriko, additional, Uchida, Naoyuki, additional, Tanaka, Masatsugu, additional, Takahashi, Satoshi, additional, Sakurai, Masatoshi, additional, Kobayashi, Hikaru, additional, Katayama, Yuta, additional, Takada, Satoru, additional, Ozeki, Kazutaka, additional, Nakamae, Hirohisa, additional, Ishimaru, Fumihiko, additional, Kanda, Yoshinobu, additional, Ichinohe, Tatsuo, additional, Atsuta, Yoshiko, additional, and Itonaga, Hidehiro, additional

Published
2023
Full Text
View/download PDF

19. Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era

Author

Ishida, Hisashi, primary, Shimada, Hiroyuki, additional, Tanizawa, Akihiko, additional, Shimazu, Yutaka, additional, Tachibana, Takayoshi, additional, Doki, Noriko, additional, Ara, Takahide, additional, Matsuo, Yayoi, additional, Nara, Miho, additional, Toubai, Tomomi, additional, Ino, Kazuko, additional, Nakamae, Hirohisa, additional, Kato, Keisuke, additional, Kato, Koji, additional, Sato, Atsushi, additional, Hino, Moeko, additional, Matsumoto, Kimikazu, additional, Atsuta, Yoshiko, additional, Yasui, Masahiro, additional, and Nagamura‐Inoue, Tokiko, additional

Published
2023
Full Text
View/download PDF

20. Data from Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia

Author

Shimazu, Yayoi, primary, Shimazu, Yutaka, primary, Hishizawa, Masakatsu, primary, Hamaguchi, Masahide, primary, Nagai, Yuya, primary, Sugino, Noriko, primary, Fujii, Sumie, primary, Kawahara, Masahiro, primary, Kadowaki, Norimitsu, primary, Nishikawa, Hiroyoshi, primary, Sakaguchi, Shimon, primary, and Takaori-Kondo, Akifumi, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure Legends from Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia

Author

Shimazu, Yayoi, primary, Shimazu, Yutaka, primary, Hishizawa, Masakatsu, primary, Hamaguchi, Masahide, primary, Nagai, Yuya, primary, Sugino, Noriko, primary, Fujii, Sumie, primary, Kawahara, Masahiro, primary, Kadowaki, Norimitsu, primary, Nishikawa, Hiroyoshi, primary, Sakaguchi, Shimon, primary, and Takaori-Kondo, Akifumi, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table S2 from Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia

Author

Shimazu, Yayoi, primary, Shimazu, Yutaka, primary, Hishizawa, Masakatsu, primary, Hamaguchi, Masahide, primary, Nagai, Yuya, primary, Sugino, Noriko, primary, Fujii, Sumie, primary, Kawahara, Masahiro, primary, Kadowaki, Norimitsu, primary, Nishikawa, Hiroyoshi, primary, Sakaguchi, Shimon, primary, and Takaori-Kondo, Akifumi, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figures from Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia

Author

Shimazu, Yayoi, primary, Shimazu, Yutaka, primary, Hishizawa, Masakatsu, primary, Hamaguchi, Masahide, primary, Nagai, Yuya, primary, Sugino, Noriko, primary, Fujii, Sumie, primary, Kawahara, Masahiro, primary, Kadowaki, Norimitsu, primary, Nishikawa, Hiroyoshi, primary, Sakaguchi, Shimon, primary, and Takaori-Kondo, Akifumi, primary

Published
2023
Full Text
View/download PDF

25. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Author

30636311, Shimazu, Yutaka, Kanda, Junya, Kosugi, Satoru, Ito, Tomoki, Kaneko, Hitomi, Imada, Kazunori, Shimura, Yuji, Fuchida, Shin-ichi, Fukushima, Kentaro, Tanaka, Hirokazu, Yoshihara, Satoshi, Ohta, Kensuke, Uoshima, Nobuhiko, Yagi, Hideo, Shibayama, Hirohiko, Yamamura, Ryosuke, Tanaka, Yasuhiro, Uchiyama, Hitoji, Onda, Yoshiyuki, Adachi, Yoko, Hanamoto, Hitoshi, Takahashi, Ryoichi, Matsuda, Mitsuhiro, Miyoshi, Takashi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, Kuroda, Junya, 30636311, Shimazu, Yutaka, Kanda, Junya, Kosugi, Satoru, Ito, Tomoki, Kaneko, Hitomi, Imada, Kazunori, Shimura, Yuji, Fuchida, Shin-ichi, Fukushima, Kentaro, Tanaka, Hirokazu, Yoshihara, Satoshi, Ohta, Kensuke, Uoshima, Nobuhiko, Yagi, Hideo, Shibayama, Hirohiko, Yamamura, Ryosuke, Tanaka, Yasuhiro, Uchiyama, Hitoji, Onda, Yoshiyuki, Adachi, Yoko, Hanamoto, Hitoshi, Takahashi, Ryoichi, Matsuda, Mitsuhiro, Miyoshi, Takashi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, and Kuroda, Junya

Published
2023

27. Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation

Author

Doki, Noriko, Suyama, Masahiro, Sasajima, Satoshi, Ota, Junko, Igarashi, Aiko, Mimura, Iyo, Morita, Hidetoshi, Fujioka, Yuki, Sugiyama, Daisuke, Nishikawa, Hiroyoshi, Shimazu, Yutaka, Suda, Wataru, Takeshita, Kozue, Atarashi, Koji, Hattori, Masahira, Sato, Eiichi, Watakabe-Inamoto, Kyoko, Yoshioka, Kosuke, Najima, Yuho, Kobayashi, Takeshi, Kakihana, Kazuhiko, Takahashi, Naoto, Sakamaki, Hisashi, Honda, Kenya, and Ohashi, Kazuteru

Published
2017
Full Text
View/download PDF

28. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Author

Shimazu, Yutaka, Kanda, Junya, Kosugi, Satoru, Ito, Tomoki, Kaneko, Hitomi, Imada, Kazunori, Shimura, Yuji, Fuchida, Shin-ichi, Fukushima, Kentaro, Tanaka, Hirokazu, Yoshihara, Satoshi, Ohta, Kensuke, Uoshima, Nobuhiko, Yagi, Hideo, Shibayama, Hirohiko, Yamamura, Ryosuke, Tanaka, Yasuhiro, Uchiyama, Hitoji, Onda, Yoshiyuki, Adachi, Yoko, Hanamoto, Hitoshi, Takahashi, Ryoichi, Matsuda, Mitsuhiro, Miyoshi, Takashi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, and Kuroda, Junya

Subjects
Multidisciplinary, Tumour immunology, Immunotherapy, Lymphocytes, Translational research, Predictive markers
Abstract

Novel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzing a real-world database in Japan. We analyzed 179 patients who underwent 201 elotuzumab treatments. The median time to next treatment (TTNT) with the 95% confidence interval was 6.29 months (5.18–9.20) in this cohort. Univariate analysis showed that patients with any of the following had longer TTNT: no high risk cytogenic abnormalities, more white blood cells, more lymphocytes, non-deviated κ/λ ratio, lower β2 microglobulin levels (B2MG), fewer prior drug regimens, no prior daratumumab use and better response after elotuzumab treatment. A multivariate analysis showed that TTNT was longer in patients with more lymphocytes (≥ 1400/μL), non-deviated κ/λ ratio (0.1–10), lower B2MG (p p

Published
2022
Full Text
View/download PDF

29. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Author

Shimazu, Yutaka, primary, Kanda, Junya, additional, Kosugi, Satoru, additional, Ito, Tomoki, additional, Kaneko, Hitomi, additional, Imada, Kazunori, additional, Shimura, Yuji, additional, Fuchida, Shin-ichi, additional, Fukushima, Kentaro, additional, Tanaka, Hirokazu, additional, Yoshihara, Satoshi, additional, Ohta, Kensuke, additional, Uoshima, Nobuhiko, additional, Yagi, Hideo, additional, Shibayama, Hirohiko, additional, Yamamura, Ryosuke, additional, Tanaka, Yasuhiro, additional, Uchiyama, Hitoji, additional, Onda, Yoshiyuki, additional, Adachi, Yoko, additional, Hanamoto, Hitoshi, additional, Takahashi, Ryoichi, additional, Matsuda, Mitsuhiro, additional, Miyoshi, Takashi, additional, Takakuwa, Teruhito, additional, Hino, Masayuki, additional, Hosen, Naoki, additional, Nomura, Shosaku, additional, Shimazaki, Chihiro, additional, Matsumura, Itaru, additional, Takaori-Kondo, Akifumi, additional, and Kuroda, Junya, additional

Published
2022
Full Text
View/download PDF

31. Prognostic impact of complex karyotype on post‐transplant outcomes of myelofibrosis

Author

Okada, Yosuke, primary, Takenaka, Katsuto, additional, Murata, Makoto, additional, Shimazu, Yutaka, additional, Tachibana, Takayoshi, additional, Ozawa, Yukiyasu, additional, Uchida, Naoyuki, additional, Wakayama, Toshio, additional, Doki, Noriko, additional, Sugio, Yasuhiro, additional, Tanaka, Masatsugu, additional, Masuko, Masayoshi, additional, Kobayashi, Hikaru, additional, Ino, Kazuko, additional, Ishikawa, Jun, additional, Nakamae, Hirohisa, additional, Matsuoka, Ken‐ichi, additional, Kanda, Yoshinobu, additional, Fukuda, Takahiro, additional, Atsuta, Yoshiko, additional, and Nagamura‐Inoue, Tokiko, additional

Published
2022
Full Text
View/download PDF

33. This title is unavailable for guests, please login to see more information.

Author

30636311, Shimazu, Yutaka, Kanda, Junya, Kaneko, Hitomi, Imada, Kazunori, Yamamura, Ryosuke, Kosugi, Satoru, Shimura, Yuji, Ito, Tomoki, Fuchida, Shin-ichi, Uchiyama, Hitoji, Fukushima, Kentaro, Yoshihara, Satoshi, Hanamoto, Hitoshi, Tanaka, Hirokazu, Uoshima, Nobuhiko, Ohta, Kensuke, Yagi, Hideo, Shibayama, Hirohiko, Onda, Yoshiyuki, Tanaka, Yasuhiro, Adachi, Yoko, Matsuda, Mitsuhiro, Iida, Masato, Miyoshi, Takashi, Matsui, Toshimitsu, Takahashi, Ryoichi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, Kuroda, Junya, 30636311, Shimazu, Yutaka, Kanda, Junya, Kaneko, Hitomi, Imada, Kazunori, Yamamura, Ryosuke, Kosugi, Satoru, Shimura, Yuji, Ito, Tomoki, Fuchida, Shin-ichi, Uchiyama, Hitoji, Fukushima, Kentaro, Yoshihara, Satoshi, Hanamoto, Hitoshi, Tanaka, Hirokazu, Uoshima, Nobuhiko, Ohta, Kensuke, Yagi, Hideo, Shibayama, Hirohiko, Onda, Yoshiyuki, Tanaka, Yasuhiro, Adachi, Yoko, Matsuda, Mitsuhiro, Iida, Masato, Miyoshi, Takashi, Matsui, Toshimitsu, Takahashi, Ryoichi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, and Kuroda, Junya

Published
2022

34. Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

Author

30636311, Onda, Yoshiyuki, Kanda, Junya, Kaneko, Hitomi, Shimura, Yuji, Fuchida, Shin-Ichi, Nakaya, Aya, Itou, Tomoki, Yamamura, Ryosuke, Tanaka, Hirokazu, Shibayama, Hirohiko, Shimazu, Yutaka, Uchiyama, Hitoji, Yoshihara, Satoshi, Adachi, Yoko, Matsuda, Mitsuhiro, Hanamoto, Hitoshi, Uoshima, Nobuhiko, Kosugi, Satoru, Ohta, Kensuke, Yagi, Hideo, Kanakura, Yuzuru, Matsumura, Itaru, Hino, Masayuki, Nomura, Shosaku, Shimazaki, Chihiro, Takaori-Kondo, Akifumi, Kuroda, Junya, 30636311, Onda, Yoshiyuki, Kanda, Junya, Kaneko, Hitomi, Shimura, Yuji, Fuchida, Shin-Ichi, Nakaya, Aya, Itou, Tomoki, Yamamura, Ryosuke, Tanaka, Hirokazu, Shibayama, Hirohiko, Shimazu, Yutaka, Uchiyama, Hitoji, Yoshihara, Satoshi, Adachi, Yoko, Matsuda, Mitsuhiro, Hanamoto, Hitoshi, Uoshima, Nobuhiko, Kosugi, Satoru, Ohta, Kensuke, Yagi, Hideo, Kanakura, Yuzuru, Matsumura, Itaru, Hino, Masayuki, Nomura, Shosaku, Shimazaki, Chihiro, Takaori-Kondo, Akifumi, and Kuroda, Junya

Abstract

Background: Little is known about the real-world survival benefits and safety profiles of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd). Methods: We performed a retrospective analysis to evaluate their efficacy and safety in 157 patients registered in the Kansai Myeloma Forum database. Results: A total of 107 patients received KRd. Before KRd, 99% of patients had received bortezomib (54% were refractory disease), and 82% had received lenalidomide (57% were refractory disease). The overall response rate (ORR) was 68.2%. The median progression-free survival (PFS) and overall survival (OS) were 8.8 and 29.3 months, respectively. Multivariate analysis showed that reduction of the carfilzomib dose and non-IgG M protein were significantly associated with lower PFS and reduction of the carfilzomib dose and refractoriness to prior bortezomib-based regimens were significantly associated with lower OS. A total of 50 patients received Kd. Before Kd, 96% of patients had received bortezomib (54% were refractory disease). The ORR was 62.0%. The median PFS and OS were 7.1 and 20.9 months, respectively. Based on the multivariate analysis, reduction of the carfilzomib dose and International Staging System Stage III (ISS III) were significantly associated with lower PFS. Grade III or higher adverse events were observed in 48% of KRd cases and 54% of Kd cases. Cardiovascular events, cytopenia, and infections were frequent, and 4 KRd patients died due to heart failure, arrhythmia, cerebral hemorrhage, and pneumonia. Conclusion: Our analysis showed that an adequate dose of carfilzomib is important for achieving the best survival benefits in a real-world setting. Adverse effects after KRd and Kd therapy should also be considered.

Published
2022

35. Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis.

Author

Suzuki, Kazuhito, Mizuno, Shohei, Shimazu, Yutaka, Fuchida, Shin‐ichi, Hagiwara, Shotaro, Itagaki, Mitsuhiro, Nishiwaki, Kaichi, Hangaishi, Akira, Karasuno, Takahiro, Kikuchi, Taku, Shimizu, Misayo, Nishikawa, Akinori, Kobayashi, Takeshi, Sunami, Kazutaka, Hiramoto, Nobuhiro, Uchiyama, Hitoji, Maruyama, Yumiko, Kanda, Yoshinobu, Ichinohe, Tatsuo, and Atsuta, Yoshiko

Subjects
OLDER patients, STEM cell transplantation, MULTIPLE myeloma, CELLULAR therapy, RETROSPECTIVE studies
Abstract

Tandem autologous stem cell transplantation (ASCT) has been reconsidered for high‐risk patients with myeloma, and the eligibility criteria for up‐front ASCT have been updated to include more elderly patients. This study aimed to evaluate the efficacy and tolerability of tandem ASCT in elderly patients with myeloma compared to tandem ASCT in young patients and single ASCT in elderly patients. A retrospective study using the Transplant Registry Unified Management Program database of the Japanese Society for Transplantation and Cellular Therapy, which included 64 elderly and 613 young patients who received tandem ASCT, and 891 elderly patients who received single ASCT, was conducted. The median overall survival (OS) over 38.5 months in the elderly and young patients who received tandem ASCT, and elderly patients who received single ASCT was 78.9, 92.5, and 77.1 months, respectively; no significant difference in the median OS was observed. The cumulative incidence of transplantation‐related mortality was similar in the elderly and young patients receiving tandem ASCT. High‐risk cytogenetic abnormality was not identified as a poor prognostic factor for OS in elderly patients who received tandem ASCT but in those who received single ASCT. Thus, tandem ASCT was effective and tolerable in elderly patients with myeloma. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. sj-docx-14-tah-10.1177_20406207221142487 – Supplemental material for Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide

Author

Shimazu, Yutaka, Kanda, Junya, Kaneko, Hitomi, Imada, Kazunori, Yamamura, Ryosuke, Kosugi, Satoru, Shimura, Yuji, Ito, Tomoki, Fuchida, Shin-ichi, Uchiyama, Hitoji, Fukushima, Kentaro, Yoshihara, Satoshi, Hanamoto, Hitoshi, Tanaka, Hirokazu, Uoshima, Nobuhiko, Ohta, Kensuke, Yagi, Hideo, Shibayama, Hirohiko, Onda, Yoshiyuki, Tanaka, Yasuhiro, Adachi, Yoko, Matsuda, Mitsuhiro, Iida, Masato, Miyoshi, Takashi, Matsui, Toshimitsu, Takahashi, Ryoichi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, and Kuroda, Junya

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-14-tah-10.1177_20406207221142487 for Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide by Yutaka Shimazu, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Ryosuke Yamamura, Satoru Kosugi, Yuji Shimura, Tomoki Ito, Shin-ichi Fuchida, Hitoji Uchiyama, Kentaro Fukushima, Satoshi Yoshihara, Hitoshi Hanamoto, Hirokazu Tanaka, Nobuhiko Uoshima, Kensuke Ohta, Hideo Yagi, Hirohiko Shibayama, Yoshiyuki Onda, Yasuhiro Tanaka, Yoko Adachi, Mitsuhiro Matsuda, Masato Iida, Takashi Miyoshi, Toshimitsu Matsui, Ryoichi Takahashi, Teruhito Takakuwa, Masayuki Hino, Naoki Hosen, Shosaku Nomura, Chihiro Shimazaki, Itaru Matsumura, Akifumi Takaori-Kondo, Junya Kuroda in Therapeutic Advances in Hematology

Published
2022
Full Text
View/download PDF

40. Efficacy of Cord Blood Transplantation for the Management of Chronic Myelomonocytic Leukemia: A Registry-Based Study in Japan

Author

Kurosawa, Shuhei, Shimomura, Yoshimitsu, Ishiyama, Ken, Fuse, Kyoko, Shimazu, Yutaka, Doki, Noriko, Uchida, Naoyuki, Tanaka, Masatsugu, Takahashi, Satoshi, Sakurai, Masatoshi, Kobayashi, Hikaru, Katayama, Yuta, Takada, Satoru, Ozeki, Kazutaka, Nakamae, Hirohisa, Ishimaru, Fumihiko, Kanda, Yoshinobu, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Itonaga, Hidehiro

Published
2023
Full Text
View/download PDF

43. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.

Author

Shimazu, Yutaka, Murata, Makoto, Kondo, Takeshi, Minami, Yosuke, Tachibana, Takayoshi, Doki, Noriko, Uchida, Naoyuki, Ozawa, Yukiyasu, Yano, Shingo, Fukuda, Takahiro, Kato, Jun, Ara, Takahide, Eto, Testuya, Ishikawa, Jun, Nakamae, Hirohisa, Tanaka, Junji, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Nagamura‐Inoue, Tokiko

Subjects
CHRONIC myeloid leukemia, STEM cell transplantation, PROTEIN-tyrosine kinase inhibitors, NILOTINIB, DASATINIB, CHRONIC leukemia, OVERALL survival, DATABASE management
Abstract

The introduction of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) treatment has dramatically improved the prognosis of CML patients and reduced the number of patients receiving allogeneic stem cell transplantation (allo‐SCT). However, the impact of the newest‐generation TKIs on the overall survival (OS) after allo‐SCT has not been well described. To investigate the beneficial effects of TKIs on the prognosis after allo‐SCT, we conducted a retrospective observational study using the Transplant Registry Unified Management Program database in Japan. We analyzed 1188 patients (male/female: 738/450; median age: 44 years; range: 16–75) who underwent their first allo‐SCT between January 2001 and December 2018. We divided the patients into two groups according to the TKI treatment used before allo‐SCT: group 1 was treated with the first generation TKI imatinib; group 2 was treated with the second generation TKIs nilotinib, dasatinib, or bosutinib and/or the third generation TKI ponatinib. We compared the post allo‐SCT OS between the two groups. The 3‐year OS rates (95%CI) of groups 1 and 2 were 59.3% (54.8%–63.5%) and 65.8% (61.6%–69.6%), respectively (p = 0.017). Multivariate analysis confirmed that group 2 had superior OS after allo‐SCT compared to group 1 (p = 0.002). Other factors associated with superior prognosis were age ≤65, performance status (PS) 0/1, a 6/6 HLA‐matched donor and chronic‐phase (CP) disease status at allo‐SCT. A subgroup analysis showed poor prognoses for patients who could not obtain a molecular response before allo‐SCT and patients with positive T315I mutation in the BCR/ABL gene. In group 2, early allo‐SCT was correlated with superior OS in patients with a blast‐crisis disease status at allo‐SCT (p = 0.001). The cumulative incidence of non‐relapse mortality rate significantly decreased in group 2 (p = 0.0005). The post allo‐SCT OS was improved both by pre‐ and post‐management of allo‐SCT and by the introduction of newer TKIs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide

Author

Shimazu, Yutaka, Kanda, Junya, Kaneko, Hitomi, Imada, Kazunori, Yamamura, Ryosuke, Kosugi, Satoru, Shimura, Yuji, Ito, Tomoki, Fuchida, Shin-ichi, Uchiyama, Hitoji, Fukushima, Kentaro, Yoshihara, Satoshi, Hanamoto, Hitoshi, Tanaka, Hirokazu, Uoshima, Nobuhiko, Ohta, Kensuke, Yagi, Hideo, Shibayama, Hirohiko, Onda, Yoshiyuki, Tanaka, Yasuhiro, Adachi, Yoko, Matsuda, Mitsuhiro, Iida, Masato, Miyoshi, Takashi, Matsui, Toshimitsu, Takahashi, Ryoichi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, and Kuroda, Junya

Subjects
multiple myeloma, monocyte, predictive markers, β2 microglobulin, Hematology, daratumumab
Abstract

Background: Daratumumab is one of the most widely used treatments for relapsed/refractory multiple myeloma (MM) patients. However, not all patients achieve a lasting therapeutic response with daratumumab. Objectives: We hypothesized that a durable response to daratumumab could be predicted by the balance between the MM tumor burden and host immune status. Design: We conducted a retrospective study using the real-world data in the Kansai Myeloma Forum (KMF) database. Methods: We retrospectively analyzed 324 relapsed/refractory MM patients who were treated with daratumumab in the KMF database. Results: In this study, 196 patients were treated with daratumumab, lenalidomide, and dexamethasone (DLd) regimen and 128 patients were treated with daratumumab, bortezomib, and dexamethasone (DBd) regimen. The median age at treatment, number of prior treatment regimens and time-to-next-treatment (TTNT) were 68, 4 and 8.02 months, respectively. A multivariate analysis showed that the TTNT under the DLd regimen was longer with either higher monocyte counts (analysis 1), higher white blood cell (WBC) counts (analysis 2), lower β2 microglobulin (B2MG Conclusion: We propose a simple scoring model to predict a durable effect of the DLd regimen by classifying patients into three categories based on either monocyte counts (0 points for ⩾200/μl; 1 point for

Published
2022
Full Text
View/download PDF

45. Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

Author

Onda, Yoshiyuki, Kanda, Junya, Kaneko, Hitomi, Shimura, Yuji, Fuchida, Shin-Ichi, Nakaya, Aya, Itou, Tomoki, Yamamura, Ryosuke, Tanaka, Hirokazu, Shibayama, Hirohiko, Shimazu, Yutaka, Uchiyama, Hitoji, Yoshihara, Satoshi, Adachi, Yoko, Matsuda, Mitsuhiro, Hanamoto, Hitoshi, Uoshima, Nobuhiko, Kosugi, Satoru, Ohta, Kensuke, Yagi, Hideo, Kanakura, Yuzuru, Matsumura, Itaru, Hino, Masayuki, Nomura, Shosaku, Shimazaki, Chihiro, Takaori-Kondo, Akifumi, and Kuroda, Junya

Subjects
KRd, carfilzomib, relapsed/refractory multiple myeloma, lenalidomide, Kd, real-world efficacy and safety, dexamethasone, Hematology
Abstract

Background: Little is known about the real-world survival benefits and safety profiles of carfilzomib–lenalidomide–dexamethasone (KRd) and carfilzomib–dexamethasone (Kd). Methods: We performed a retrospective analysis to evaluate their efficacy and safety in 157 patients registered in the Kansai Myeloma Forum database. Results: A total of 107 patients received KRd. Before KRd, 99% of patients had received bortezomib (54% were refractory disease), and 82% had received lenalidomide (57% were refractory disease). The overall response rate (ORR) was 68.2%. The median progression-free survival (PFS) and overall survival (OS) were 8.8 and 29.3 months, respectively. Multivariate analysis showed that reduction of the carfilzomib dose and non-IgG M protein were significantly associated with lower PFS and reduction of the carfilzomib dose and refractoriness to prior bortezomib-based regimens were significantly associated with lower OS. A total of 50 patients received Kd. Before Kd, 96% of patients had received bortezomib (54% were refractory disease). The ORR was 62.0%. The median PFS and OS were 7.1 and 20.9 months, respectively. Based on the multivariate analysis, reduction of the carfilzomib dose and International Staging System Stage III (ISS III) were significantly associated with lower PFS. Grade III or higher adverse events were observed in 48% of KRd cases and 54% of Kd cases. Cardiovascular events, cytopenia, and infections were frequent, and 4 KRd patients died due to heart failure, arrhythmia, cerebral hemorrhage, and pneumonia. Conclusion: Our analysis showed that an adequate dose of carfilzomib is important for achieving the best survival benefits in a real-world setting. Adverse effects after KRd and Kd therapy should also be considered.

Published
2022
Full Text
View/download PDF

46. Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis

Author

Murata, Makoto, SUZUKI, Ritsuro, Nishida, Tetsuya, Shirane, Shuichi, Shimazu, Yutaka, Minami, Yosuke, Mori, Takehiko, Doki, Noriko, Kanda, Yoshinobu, Uchida, Naoyuki, Tanaka, Masatsugu, Ishikawa, Jun, Togitani, Kazuto, Fukuda, Takahiro, Ichinohe, Tatsuo, Atsuta, Yoshiko, Nagamura-Inoue, Tokiko, Kiyoi, Hitoshi, Murata, Makoto, SUZUKI, Ritsuro, Nishida, Tetsuya, Shirane, Shuichi, Shimazu, Yutaka, Minami, Yosuke, Mori, Takehiko, Doki, Noriko, Kanda, Yoshinobu, Uchida, Naoyuki, Tanaka, Masatsugu, Ishikawa, Jun, Togitani, Kazuto, Fukuda, Takahiro, Ichinohe, Tatsuo, Atsuta, Yoshiko, Nagamura-Inoue, Tokiko, and Kiyoi, Hitoshi

Published
2020

49. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis

Author

Takakuwa, Teruhito, primary, Yamamura, Ryosuke, additional, Ohta, Kensuke, additional, Kaneko, Hitomi, additional, Imada, Kazunori, additional, Nakaya, Aya, additional, Fuchida, Shin‐ichi, additional, Shibayama, Hirohiko, additional, Matsuda, Mitsuhiro, additional, Shimazu, Yutaka, additional, Adachi, Yoko, additional, Kosugi, Satoru, additional, Uchiyama, Hitoji, additional, Tanaka, Hirokazu, additional, Hanamoto, Hitoshi, additional, Shimura, Yuji, additional, Kanda, Junya, additional, Onda, Yoshiyuki, additional, Uoshima, Nobuhiko, additional, Yagi, Hideo, additional, Yoshihara, Satoshi, additional, Hino, Masayuki, additional, Shimazaki, Chihiro, additional, Takaori‐Kondo, Akifumi, additional, Kuroda, Junya, additional, Matsumura, Itaru, additional, Kanakura, Yuzuru, additional, and Nomura, Shosaku, additional

Published
2021
Full Text
View/download PDF

50. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era

Author

Tomita, Naoto, Yokoyama, Masahiro, Yamamoto, Wataru, Watanabe, Reina, Shimazu, Yutaka, Masaki, Yasufumi, Tsunoda, Saburo, Hashimoto, Chizuko, Murayama, Kayoko, Yano, Takahiro, Okamoto, Rumiko, Kikuchi, Ako, Tamura, Kazuo, Sato, Kazuya, Sunami, Kazutaka, Shibayama, Hirohiko, Takimoto, Rishu, Ohshima, Rika, Hatta, Yoshihiro, Moriuchi, Yukiyoshi, Kinoshita, Tomohiro, Yamamoto, Masahide, Numata, Ayumi, Ishigatsubo, Yoshiaki, and Takeuchi, Kengo

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results